Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?
Europace · 01.11.2024 · 26 (11)
DOI: 10.1093/europace/euae280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Europace, online erschienen am 10.11.2024. Verfasst von Hiroyuki Yoshimura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Informatics Research, University College London, 222 Euston Road, London NW1 2DA, UK. Hauptthemen laut MEDLINE: Atrial Fibrillation, Thromboembolism. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, senior investigator, AFFIRMO.
Abstract (Originalsprache)
Aims
The CHA2DS2VASc score is recommended for stroke risk stratification in patients with atrial fibrillation (AF). This score assigns one extra point to female sex based on evidence from the early 2000s, suggesting higher thromboembolic risk in women. This incremental risk of thromboembolism in women has decreased over time between 2007 and 2018, becoming non-significant in recent years. The objective of this study was to assess the impact of removing the sex category (Sc) from the CHA2DS2VASc score, thus validating a non-sex CHA2DS2VASc (i.e. CHA2DS2VA) score. Methods and results We analysed UK primary and secondary care data comprising 195 719 patients with AF followed between 1998 and 2016 (mean age: 75.9 ± 12.3 years; 49.2% women). Among 126 428 non-anticoagulated patients, we compared the CHA2DS2VASc vs. CHA2DS2VA scores every calendar year. Throughout 413 007 patient-years, a total of 8742 events of ischaemic stroke or systemic embolism were recorded. Sex differences in thromboembolic risk were not observed in the lower-risk population, but higher stroke rates were consistently seen in female patients in the higher-risk category (i.e. CHA2DS2VA ≥2). C-statistics for both CHA2DS2VA and CHA2DS2VASc scores were similar over the years (ranging from 0.62 to 0.71). With CHA2DS2VA, no relevant differences were observed in integrated discrimination improvement, and net reclassification improvement (NRI) resulted in improved reclassification (11%) in lower thromboembolic risk groups. The NRI suggested misclassification in higher thromboembolic risk patients (−7%), but this did not affect their indication for anticoagulation (i.e. patients retained their high-risk status).
Conclusion
Removing Sc from the CHA2DS2VASc score does not affect its ability to discriminate thromboembolic events in the population with AF. The use of CHA2DS2VA may simplify initial decision-making for thromboprophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Health Informatics Research, University College London, 222 Euston Road, London NW1 2DA, UK.
- Barts Heart Centre, Barts Health NHS Trust, London, UK.
- Institute of Cardiovascular Science, University College London, London, UK.
- Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
- Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark.
ORCID-Profile: Hiroyuki Yoshimura, Rui Providencia, Chris Finan, Amand Floriaan Schmidt, Gregory Y H Lip
Förderung
- National Institute for Health and Care Research
- senior investigator
- AFFIRMO
- European Union's Horizon 2020 Research and Innovation Programme
- University College London British Heart Foundation Research
- European Union’s Horizon 2020 Research and Innovation Programme
Zitieren
APA
Yoshimura, H., Providencia, R., Finan, C., Schmidt, A. F., & Lip, G. Y. H. (2024). Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?. Europace, 26(11). https://doi.org/10.1093/europace/euae280
Vancouver
Yoshimura H, Providencia R, Finan C, Schmidt AF, Lip GYH. Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?. Europace. 2024;26(11). doi:10.1093/europace/euae280
BibTeX
@article{Yoshimura2024,
author = {Yoshimura, Hiroyuki and Providencia, Rui and Finan, Chris and Schmidt, Amand Floriaan and Lip, Gregory Y H},
title = {Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?},
journal = {Europace},
year = {2024},
volume = {26},
number = {11},
doi = {10.1093/europace/euae280}
}
EUVIMED